Obesity

Global Antibody Drug Conjugates Market Research Report 2021: COVID-19 Growth and Change to 2025 & 2030 - ResearchAndMarkets.com

Friday, October 22, 2021 - 12:13pm

The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The challenges involved in the manufacturing of ADC's is acting as a restraint on the antibody drug conjugates market.
  • Global Antibody Drug Conjugates Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
    6.2.
  • Global Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Global Salmon Market (2021 to 2028) - Rise in Fish Production to Meet Food Supply is Driving Growth - ResearchAndMarkets.com

Thursday, October 21, 2021 - 5:27pm

In addition, most Atlantic salmon are available in the global market are farmed, whereas the majority of Pacific salmon are wild-caught.

Key Points: 
  • In addition, most Atlantic salmon are available in the global market are farmed, whereas the majority of Pacific salmon are wild-caught.
  • The growing demand for salmon in emerging markets like Asia-Pacific and Latin America is offering lucrative growth opportunities to the players operating in the global salmon market.
  • Moreover, demand for eco-labelled farmed salmon is rising rapidly and preference for fresh food products is trending in the salmon market.
  • The report provides a quantitative analysis of the current market, estimations, trends, and dynamics of the global salmon market size from 2020 to 2028 to identify the prevailing market opportunities.

Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain

Thursday, October 21, 2021 - 3:13pm

CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive data in a pre-clinical model of pain reduction. Based on this positive data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., has selected PNV-5030 as the lead compound for its program to develop a drug for the treatment of pain.

Key Points: 
  • Based on this positive data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., has selected PNV-5030 as the lead compound for its program to develop a drug for the treatment of pain.
  • However, PNV-5030 has demonstrated solubility more than 50 times greater than other known selective adenosine compounds of the same class.
  • PNV-5030 alone exhibited a significant pain reduction as compared to the control group and a similar effect to 1mg/kg morphine.
  • Interestingly, when combined with 1 mg/kg morphine, PNV-5030 achieved a similar level of pain reduction to the reduction obtained with 2mg/kg morphine.

Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain

Thursday, October 21, 2021 - 2:45pm

CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive data in a pre-clinical model of pain reduction. Based on this positive data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., has selected PNV-5030 as the lead compound for its program to develop a drug for the treatment of pain.

Key Points: 
  • Based on this positive data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., has selected PNV-5030 as the lead compound for its program to develop a drug for the treatment of pain.
  • However, PNV-5030 has demonstrated solubility more than 50 times greater than other known selective adenosine compounds of the same class.
  • PNV-5030 alone exhibited a significant pain reduction as compared to the control group and a similar effect to 1mg/kg morphine.
  • Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders.

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

Thursday, October 21, 2021 - 12:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211021005526/en/
    Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal (Photo: Business Wire)
    The article includes highlights from Can-Fites Phase IIa NASH study of Namodenoson which achieved its study endpoints including significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects.
  • Namodenoson is advancing into a Phase IIb NASH trial which is expected to commence patient enrollment in Q4 2021.
  • Principal Investigator of the Phase IIa study, Prof. Rifaat Safadi, commented, The acceptance and publication of the article presenting our Phase IIa results in this prestigious journal demonstrates the high value of the data and the potential of Namodenoson as safe and effective treatment for NASH.
  • As of 2016, NASH was the leading cause for liver transplants among women and the second leading cause for liver transplants overall.

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

Wednesday, October 20, 2021 - 10:07pm

While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.

Key Points: 
  • While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.
  • The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.
  • The NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial was a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Global Fitness App Market Report 2021-2026 - Snowballing Fitness Consciousness a Major Driver - ResearchAndMarkets.com

Wednesday, October 20, 2021 - 5:20pm

The "Global Fitness App Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Fitness App Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the Global Fitness App Market attributes to the increasing smartphone users and constant technological evolutions.
  • Based on the type, the Workout and Exercise Apps segment acquired the largest market share in the global fitness app market in 2019.
  • Thus, this contributes to the growth of the fitness app market, reveals the author in their research report, Global Fitness App Market Analysis, 2021.

Bardavon Health Innovations Secures $90 Million in Series C Funding to Advance True MSK Technology Platform Beyond Workers’ Compensation Care

Wednesday, October 20, 2021 - 4:16pm

Bardavon, a privately held, Kansas City-based digital health partner, connects all stakeholders to better manage MSK injuries and health.

Key Points: 
  • Bardavon, a privately held, Kansas City-based digital health partner, connects all stakeholders to better manage MSK injuries and health.
  • We started this company with an eye toward revolutionizing and disrupting the Workers Compensation industry, said Matthew Condon, Founder and CEO of Bardavon.
  • Our research shows that Americas largest employers are desperate for a viable MSK health, wellness, and care solution.
  • Bardavon is a privately held proactive Workers Compensation and MSK digital health partner that connects all stakeholders to better manage claims.

Global High Potency Active Pharmaceutical Ingredients Market to 2028 - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Wednesday, October 20, 2021 - 1:16pm

The "High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global high potency active pharmaceutical ingredients market size is expected to reach USD 38.84 billion by 2028, according to a new report by the publisher It is expected to expand at a CAGR of 8.4% from 2021 to 2028.
  • The market is driven by an increased focus on targeted therapies and a surge in demand for cancer therapies.
  • The rising prevalence of cancer is a major factor expected to drive the market for high potency active pharmaceutical ingredients (HPAPIs).

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Wednesday, October 20, 2021 - 1:00pm

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. Rhythm’s precision medicine, IMCIVREE (setmelanotide), was approved in November 2020 by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and in July and September 2021, respectively, by the European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE is the first-ever FDA-approved and EC- and MHRA-authorized therapy for patients with these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 37,500 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • ET on Tuesday, November 2, 2021 to report its third quarter 2021 financial results and provide a corporate update.
  • To access the live conference call, please dial (844) 498-0570 (domestic) or (409) 983-9726 (international) and refer to conference ID 2167009.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.